Key facts: Edwards Raises Guidance; FDA Approvals; CMS TAVR Rules

What happened

Edwards Lifesciences reported third-quarter sales of $1.72 billion, up 10.5%, and adjusted earnings per share of $0.80, both above estimates. It raised its 2026 growth guidance, received U.S. FDA approvals for two repair devices, and CMS finalized updated U.S. coverage rules for TAVR.

Confirmed

Global impact / market context

Higher guidance and sales growth point to stronger expected business activity, while device approvals may widen the treatments Edwards can offer. Updated Medicare coverage rules could make TAVR available to more patients sooner, potentially supporting procedure volumes and revenue, though the article gives no financial estimate.

Analyst inference

The article combines company results and regulatory developments with a broker upgrade, but reports no share-price reaction. For investors, the key link is whether stronger sales and broader access translate into sustained procedure growth, revenue, and profit per sale after the costs of expanding products and operations.

Analyst inference

What to watch

1. Look for Edwards’ detailed 2026 growth guidance and later results to show whether the raised outlook is supported by continued TAVR and TMTT sales growth. Analyst inference
2. Track how hospitals implement CMS’s finalized TAVR coverage rules and whether the company reports changes in patient access or procedure volumes. Analyst inference
3. Watch for further U.S. or European regulatory decisions affecting PASCAL or EVOQUE, which could determine where these repair devices can be used. Analyst inference

Evidence

• Original source link unavailable